

The role of automated insulin delivery technology in diabetes

Charlotte K Boughton (0000-0003-3272-9544) and Roman Hovorka (0000-0003-2901-461X)

Wellcome-Medical Research Council Institute of Metabolic Science,
University of Cambridge, Cambridge, UK

Corresponding author

Charlotte Boughton MD PhD

University of Cambridge Metabolic Research Laboratories and
NIHR Cambridge Biomedical Research Centre,
Wellcome-MRC Institute of Metabolic Science, Box 289,
Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK
tel: +44 1223 769 066, e-mail: cb2000@medschl.cam.ac.uk

Manuscript word count: 3511

Abstract word count: 108

References 63

Visuals:

Table: 1

Figures: 2

Key words: automated insulin delivery, closed-loop, artificial pancreas, type 1 diabetes, type 2 diabetes

Twitter/X: The role of automated insulin delivery systems in diabetes is expanding. We review emerging indications for closed-loop systems, discuss challenges around access and implementation, and consider innovative approaches to improve performance. @ckboughton @_RomanHovorka @IMS_MRL

Graphical abstract created with Biorender.

Abstract

The role of automated insulin delivery systems in diabetes is expanding. Hybrid closed-loop systems are being used in routine clinical practice in type 1 diabetes. Encouragingly, real-world data reflects the performance and usability observed in clinical trials. We review the commercially available hybrid closed-loop systems, their distinctive features and the associated real-world data.

We consider emerging indications for closed-loop systems including type 2 diabetes where variability of day-to-day insulin requirements is high, and other challenging applications for this technology.

We discuss issues around access and implementation of closed-loop, and consider limitations of present closed-loop systems and innovative approaches which are being evaluated to improve performance of closed-loop systems.

Introduction

Automated insulin delivery systems, also called closed-loop systems or artificial pancreas, have successfully transitioned from the research bench to becoming the standard of care for people with type 1 diabetes. This success story is at least in part due to the need for improved treatment strategies and reduced disease burden for the growing population living with diabetes.

Despite the increasing use of insulin pumps and glucose sensors for people with type 1 diabetes, the introduction of new oral and non-insulin injectable therapies for type 2 diabetes, and the continual advancements in modern insulin analogues, registry data from the US and Europe estimates that the ADA recommended glycaemic target (HbA1c <7% (53mmol/mol) without significant hypoglycemia) is met by only a quarter of people with type 1 diabetes and half of those with type 2 diabetes (1, 2). This highlights a clear need to improve diabetes management approaches and outcomes for both type 1 and type 2 diabetes to prevent the risk of micro and macrovascular complications and hospital admissions. However, resources including access to healthcare professionals are limited and the demand is growing. Globally, 1 in 10 adults are living with diabetes (537 million) and this number is predicted to rise by 100 million over the next 10 years (3).

Closed-loop systems are addressing this need for improved diabetes management, and the related infrastructure required to effectively deliver these solutions, diabetes technology 'ecosystems', have emerged. The ecosystems comprise not only the hardware components of the system i.e. insulin pump and glucose sensor, and the algorithm, but also training resources for users and healthcare professionals, customer support, data sharing platforms, and follower functionality allowing relatives or caregivers to directly view data on their own device, which all impact on the user experience (Figure 1).

Clinical benefits of closed-loop systems for people living with diabetes

The benefits of closed-loop systems on glucose control are well established across people of all ages with type 1 diabetes, including pregnant women (4). Hybrid closed-loop systems, requiring meal announcement while insulin delivery between meals and overnight is automated, improve glucose control without increasing hypoglycaemia, or in some cases reduce hypoglycaemia. Meta-analyses undertaken from trial data in adults and in children show that hybrid closed-loop systems out-perform non-automated systems with improvements in time spent in target glucose range of approximately 8-12 percentage points, reduced time spent in hyperglycaemia, reduced mean glucose and either a reduction or no increase in time in hypoglycaemia (5-7). User characteristics that influence the clinical impact of hybrid closed-loop include baseline glucose control, with the greatest improvements observed where the baseline HbA1c is highest and time in range lowest (8, 9). Optimal performance with hybrid closed-loop systems is associated with increased bolus frequency and a higher proportion of total daily insulin delivered as bolus (10, 11).

The evidence evaluating closed-loop systems for people with type 2 diabetes is less well established, but interest in this area growing. Small randomised controlled cross-over trials have shown improved glucose control without an increase in hypoglycaemia compared to standard insulin therapy in adults with type 2 diabetes and sub-optimal glucose control at baseline using a fully automated closed-loop system (CamAPS HX, Camdiab, UK), which does not require any meal announcement, in the outpatient setting (12, 13). The same fully closed-loop system has also shown safety and efficacy in inpatients during acute hospital admissions (14, 15). The benefit of a fully closed-loop system in this setting is that it removes the need for healthcare professional input for insulin dosing decisions, which are often inaccurate due to the unpredictability of these situations. Hybrid closed-loop systems (Control-IQ, Tandem, CA, USA and Omnipod 5, Insulet, MA, USA) have also shown feasibility in adults with type 2 diabetes in an outpatient setting in non-randomised studies and real-world data (16, 17). Increased insulin resistance with greater daily insulin requirements in those with type

2 diabetes may necessitate insulin pumps with larger reservoir capacity or use of concentrated insulins in the closed-loop system.

Automated insulin delivery has also been evaluated in a small study of people with cystic fibrosis related diabetes (CFRD) over a period of 14 days where there was improved time in target glucose range without an increase in hypoglycaemia compared to usual care (18).

Psychosocial impact of closed-loop systems for people living with diabetes

Equally, or perhaps more importantly than the clinical benefits of closed-loop systems are the potential psychosocial benefits in reducing the burden of diabetes management. Improvements in person-reported outcome measures associated with closed-loop have been inconsistent, which may relate to study design, population and length of follow-up, but all studies have shown that even if there was no improvement in quality-of-life, there was no deterioration. Specific benefits reported by closed-loop users include reduced diabetes distress, reduced fear of hypoglycemia, and improved quality of sleep. Meta-analysis data of person-reported outcome measures from hybrid closed-loop trials longer than three months found decreased diabetes distress and a tendency for reduced fear of hypoglycaemia but no significant difference in treatment satisfaction (19). Perceived drawbacks include connectivity problems, automation-related errors, pump glitches, and other issues associated with insulin pumps. Evaluation of fully automated closed-loop systems may result in further improvements in quality-of-life and treatment satisfaction.

Qualitative interviews provide richer and more in-depth user experiences of closed-loop systems. Many users, including children and adults with type 1 diabetes describe the technology as 'life-changing', associating it with improved well-being and facilitating a greater sense of normality (20-22). For some people it has even facilitated a return to paid employment. The psychosocial benefits of closed-loop have also been reported to extend to family members including parents, partners and children of people with diabetes (20, 23).

Pregnant women using closed-loop described how it lessened the demands of diabetes management, enabling them to feel more normal and sleep better (24). All women reported more enjoyable pregnancy experiences as a result of using closed-loop.

It is important to note that reports of user experiences from closed-loop studies are limited by the relative lack of ethnic and socioeconomic diversity of the research study populations (25). There are also limited reports of the psychosocial impact of closed-loop systems from real-world settings. There are very limited reports of the psychosocial impact of closed-loop technology in adults with type 2 diabetes or those with cystic fibrosis related diabetes (12, 18).

Commercially available closed-loop systems for people with type 1 diabetes

The current commercially available closed-loop systems are hybrid systems requiring the user to announce meals. Each system has distinct features which may benefit specific user groups (Table 1).

The first-generation Medtronic hybrid closed-loop system (MiniMed 670G, Medtronic, CA, USA) has been superseded by the second generation MiniMed 780G which has improved usability (reduced auto mode exits and alarms) and improved glucose control with automated bolus insulin corrections and a meal detection module in addition to the existing features of the MiniMed 670G (26). The MiniMed 780G also benefits from the calibration-free Guardian 4 sensor and compatibility with Apple Watch. Its licence is for people with type 1 diabetes age 7 and above.

Control-IQ hybrid closed-loop algorithm, hosted on the t:slim X2 insulin pump (Tandem, CA, USA), uses pre-programmed basal rates, correction factor, and carbohydrate to insulin ratio as part of its algorithm inputs, while the correction target and active insulin time are fixed in the system (27). The system benefits from a choice of compatible sensors (Dexcom G6/G7,

Dexcom, CA, USA; Freestyle Libre 2 Plus, Abbott Diabetes Care, CA, USA). Its licence is for people with diabetes requiring insulin age 6 and above.

Diabeloop DBLG1 hybrid closed-loop algorithm (Diabeloop, France), hosted on a dedicated controller handset, is based on machine-learning within a physiological framework with an expert system and self-learning algorithm. DBLG1 allows users to customise the algorithm through ten different settings including target glucose level and hypoglycaemia threshold (28). Its licence is for people with type 1 diabetes age 18 and above. Diabeloop for highly unstable type 1 diabetes (DBLHU) is a hybrid closed-loop system derived from the DBLG1 which is licenced for the indication of unstable diabetes.

CamAPS FX (CamDiab, UK) is an Android app-based hybrid closed-loop system designed to be inter-operable with different insulin pumps (Ypsopump, Ypsomed, Switzerland; Dana, Sooil, South Korea) and sensors (Dexcom G6 and Freestyle Libre 3). The system requires weight and total daily insulin dose for initialisation, while the adaptive algorithm calculates and adjusts insulin sensitivity, carbohydrate bioavailability, and active insulin time. The system benefits from a wide range of target glucose settings (4.4 to 11.1mmol/L) and can be used with rapid and ultra-rapid insulins. Its licence is for people with diabetes age 1 and upwards and includes pregnant women.

Omnipod 5 is the first hybrid closed-loop system which utilises a tubeless/patch pump receiving data directly from the Dexcom G6 glucose sensor. The adaptive features of the control algorithm, hosted on a dedicated controller handset, use the average total daily insulin to update the adaptive basal rate, giving a new baseline for automated insulin delivery with each pump change. Target glucose is the only adjustable setting (6.1 to 8.3mmol/L) that directly impacts automated insulin delivery. Its licence is for people with type 1 diabetes age 2 and above.

The iLet bionic pancreas (BetaBionics, CA, USA) uses an adaptive closed-loop algorithm that initialises with the user's body weight and requires no additional insulin dosing parameters

(29). This eliminates the need to determine pre-set basal rates, insulin-to-carbohydrate ratios or correction factors which are calculated by the algorithm. The system simplifies mealtimes with a meal announcement feature allowing users to estimate the amount of carbohydrates in the meal. Its licence is for people with type 1 diabetes age 6 and older.

The lengthy and complex development and approval processes required for commercial closed-loop systems, along with access and reimbursement limitations, gave rise to open-source closed-loop systems (30). These so-called 'do-it-yourself' systems have been created and supported by online communities who generate resources providing detailed instructions for set-up and use. Open-source systems are designed for considerable user customisation allowing adjustment of algorithm parameters, include specific functionalities and have a range of compatible devices and user interfaces. Limitations include the need for a level of health and digital literacy above the general population to set-up and maintain the system with updates having to be performed manually by the user.

Real-world evidence for closed-loop systems in type 1 diabetes

Real-world data from commercial closed-loop systems demonstrate the performance and acceptance of this technology outside of the trial setting (31). Reassuringly, outcomes are similar to those reported in the pivotal studies in terms of efficacy (time spent in target glucose range and hypoglycaemia exposure) and usability (time spent in closed-loop mode). Comparisons between closed-loop systems with regards to efficacy and safety are limited by differences in underlying characteristics of users.

Data from over 100,000 Medtronic 780G users across Europe, the Middle East and Africa showed that time spent in closed-loop mode was 90%, while time spent in target glucose range (3.9 to 10.0mmol/L) was 72.3% with 2.0% of time spent below target range (32). Real-world data shows that optimal glucose control is associated with applying the lowest glucose target setting (5.5mmol/L) and the shortest active insulin time setting (2 hours) (33).

Data from over 20,000 Control-IQ users in the US were analysed. The time spent in target glucose range was 71.5% with 1% time spent below target range. More aggressive correction factor settings, insulin-to-carbohydrate ratio settings, and basal programs were all associated with higher time in range but also, to a lesser degree, to higher time below target (34). Real-world usability has been reported in a smaller dataset (>9,000 users) where time spent in closed-loop mode was 94% (35).

Adult Diabeloop users (>3,500) in Germany spent 95% of time in closed-loop mode. The percentage time in target glucose range was 72.1% and time spent below 3.9mmol/L was 0.9% (36).

Data from 1,800 CamAPS FX users from 15 countries across a wide range of age groups showed that users spent 95% of time in closed-loop mode. Time in target glucose range was 72.6% and increased by age from 66.9% for users ≤ 6 years old to 81.8% for users ≥ 65 years. Time spent in hypoglycemia (<3.9mmol/L) was 2.3% (37).

Real-world data-set from nearly 70,000 Omnipod 5 users (aged ≥ 2 years) in the US showed that users spent 94% of time in closed-loop mode, while time in target glucose range was 64.2% with 1.0% of time spent in hypoglycaemia (<3.9mmol/L) (38).

A real-world data-set of 558 adults and children using open-source systems showed that the time spent in closed-loop mode was 83%. Time in target glucose range was 73% and time with glucose <3.9mmol/L was 2.8% (39).

An NHS England pilot study evaluating real-world implementation of hybrid closed-loop included 251 children and 570 adults with type 1 diabetes (40, 41). Of 226 children and young people with complete data at 6 months, HbA1c was reduced by 0.7 percentage points and time in target glucose range (3.9 to 10.0mmol/L) increased from 49% to 63%. There was also a significant reduction in time in hypoglycaemia. Of 520 adult users continuing hybrid closed-loop at 6 months, HbA1c reduced by 1.7 percentage points, time in target glucose range increased from 34% to 62% and there was a significant reduction in time in hypoglycaemia.

Challenging applications for closed-loop systems

While the clinical benefits of closed-loop systems appear to extend to all user groups, there are some populations where the need for glucose-responsive insulin delivery is particularly important. Data obtained from secondary analysis of closed-loop studies highlights specific populations where the day-to-day variability of insulin requirements are greatest, and therefore self-adjustment of insulin doses in response to glucose trends may be the most challenging.

Adults with type 2 diabetes

The population with the highest variability of day-to-day insulin requirements is adults with type 2 diabetes (42) (Figure 2). This is perhaps surprising given the presence of residual endogenous insulin secretion, but perhaps explains the challenge that many people with type 2 diabetes and healthcare providers face in reaching glycaemic targets with standard insulin therapy. Inpatients with type 2 diabetes have lower variability of day-to-day insulin requirements than outpatients despite the effect of the stress of acute illness, medications which exert effects on glycaemia and periods of fasting for inpatient investigations or procedures. This may reflect more sedentary behaviour and reduced oral intake during a hospital admission.

Very young children with type 1 diabetes

The greatest variability in day-to-day insulin requirements in those with type 1 diabetes is in very young children (43). Additional challenges of inconsistent meal consumption, unannounced activity and inability to articulate symptoms of hypoglycaemia make this population arguably the most important to benefit from closed-loop systems. The impact on caregivers and other family members of very young children with type 1 diabetes is also profound (20).

Pregnant women with diabetes

Attaining recommended tight glucose control during pregnancy is particularly difficult due to marked gestational variations in insulin sensitivity and altered eating patterns (44). For pregnant women with type 1 diabetes, improved maternal glucose control is associated with reduced risk of large for gestational age infants, neonatal hypoglycaemia and neonatal intensive care unit admissions (45). Recent evidence shows that the CamAPS FX hybrid closed-loop, which unlike other commercially available systems allows users to set glucose targets at the recommended pregnancy targets, improves time spent in the tight target glucose range (3.5 to 7.8mmol/L) during pregnancy for women with type 1 diabetes compared to standard insulin therapy without increasing time spent in hypoglycaemia (<3.5mmol/L) (46). It remains to be seen if the same benefits are observed for pregnant women with type 2 diabetes or those with gestational diabetes requiring insulin.

People with diabetes and impaired awareness of hypoglycaemia

Closed-loop systems may benefit individuals with long-standing diabetes where frequent exposure to hypoglycemia impairs counterregulatory responses resulting in hypoglycaemia unawareness. In adults with type 1 diabetes at high risk for hypoglycemia (Clarke score >3 and/or a history of severe hypoglycemia during the previous 6 months), hybrid closed-loop significantly reduced time spent in hypoglycaemia (<3.9mmol/L) compared to baseline, while improving time in target glucose range (3.9 to 10.0mmol/L) (47). Despite the reduction in hypoglycaemia, there was no improvement in self-reported hypoglycaemia awareness. Conversely, a small non-randomised study in 10 adults with long-standing type 1 diabetes showed that use of hybrid closed-loop for 18 months reduced severe hypoglycemia events and improved hypoglycemia awareness (48). This was associated with increased adrenaline secretion and improved autonomic symptoms in hypoglycaemic clamp studies.

Frail people with diabetes and cognitive impairment

New challenges are arising in the optimal management of the frail, elderly and those with cognitive impairment who require assistance with their diabetes management. Closed-loop systems have not yet been robustly evaluated in this user group. Potential benefits of closed-loop systems in this population include operation using an off-body handset, availability of alerts for dangerous glycaemic excursions and the capability to review data remotely. Training of caregivers to use the closed-loop system is likely to be challenging, and acceptance of wearing the devices may be an issue for some people.

Challenges to implementation of closed-loop

It is clear that closed-loop technology has brought positive life-changing experiences for many users. The greatest challenge at present is to ensure that these benefits can be extended widely to people living with diabetes, and in particular, more underserved populations: those from lower socioeconomic groups, ethnic minority groups and those with poorer health literacy.

Country-specific reimbursement policies are a key factor determining access to closed-loop systems. In England and Wales, recent National Institute for Health and Care Excellence (NICE) guidance mandates that hybrid closed-loop is recommended as an option for all children and young people with type 1 diabetes and for adults with type 1 diabetes and sub-optimal glucose control, or with disabling hypoglycaemia, despite best possible alternative management (49). Reimbursement across European countries varies considerably from 100% reimbursement to very limited reimbursement with or without co-pay and in the US reimbursement is determined by insurance coverage or ability to meet costs (50).

Training received by users and the ongoing clinical support is an integral part of the closed-loop ecosystem (Figure 1). To ensure widespread access to this technology, healthcare professionals need to be familiar with the rapidly expanding commercially available closed-

loop systems. In addition, appropriate education material needs to be developed that is high quality, efficient, and accessible to enable effective implementation. To support equitable roll out the closed-loop training resources need to be available in multiple languages. While some training and support can be taken on by the closed-loop companies, some will inevitably fall on already overburdened healthcare providers. Healthcare professional workload and bias are important contributors to inequalities in access to this technology for people with diabetes (51). Standardised clinical outcome reporting on a common 'diabetes data platform' would facilitate users and healthcare professionals to get the most out of the technology, but is challenging with data protection legislation.

Regulatory hurdles can be onerous for the approval of new closed-loop devices (class III devices under EU Medical Device Regulation), particularly those with the capacity for interoperability (a unique approach devised by the FDA: alternate controller-enabled insulin pumps, integrated CGM systems and interoperable automated glycaemic controller devices). The lack of choice of interoperable devices at present may negatively impact the user experience. Other barriers to use of this technology include the physical burdens associated with wearing the devices and psychosocial burdens associated with alarm burden and device reliability issues. Usability, reflected by a sustained high time spent in automated mode (>95%), is critical to realising the clinical benefits of closed-loop systems (52).

What does the future of automated insulin delivery look like?

Closed-loop technology is fast becoming the standard of care for people with type 1 diabetes but work needs to be undertaken to ensure that barriers to access to closed-loop do not widen the current gap in health outcomes in underserved communities. The technology has the potential to bridge this gap if access is equitable and conscious and unconscious bias can be avoided.

Reducing device burden with smaller on-body devices (insulin pump and sensors), longer duration wear time and improved reliability would increase the appeal of closed-loop systems. Expansion of interoperable closed-loop components, which offer wider user choice and customisation compared to integrated closed-loop systems, may also positively impact user experience.

Managing glucose excursions associated with meals and exercise remains challenging with current commercial hybrid closed-loop systems and future research needs to address these limitations. While hybrid closed-loop systems are the mainstay of automated insulin delivery, there is a growing role for artificial intelligence generated insights and advice to support users attain optimal glucose control. This may be obviated if a safe and effective fully automated insulin delivery solution becomes commercially available. Potential solutions include the application of ultra-rapid acting insulins with faster on and faster off profiles in closed-loop systems, dual hormone closed-loop systems or adjuncts alongside closed-loop. Ultra-rapid insulins have the potential to improve closed-loop performance (53-56), however use of ultra-rapid Lispro in a fully closed-loop system which reduces burden came at the expense of optimal glucose control (57). Dual hormone closed-loop systems using insulin and pramlintide or insulin and glucagon have been evaluated in clinical trials but add complexity and cost, and are associated with gastro-intestinal side effects (58, 59). Adjuncts targeting post-prandial glucose control, such as GLP-1 receptor agonists and SGLT-2 inhibitors may allow for a fully closed-loop system with small studies showing feasibility, however there are concerns around an increased risk of diabetic ketoacidosis (60, 61). Given the immediate and marked improvement in glucose control observed after initiation of closed-loop, longer-term follow up of users is required to investigate the potential development of diabetic retinopathy.

Innovative approaches to improving performance of closed-loop systems include incorporation of signals from other wearables such as a smartwatch app which detects eating behaviour (62) or a fitness sensor for detecting exercise/activity (63). The potential clinical benefits of integrating these devices remains to be determined in larger and longer trials. Safety

enhancements of closed-loop systems may include integration of a combined continuous glucose-ketone monitor or an infusion set failure detection system. Additional monitoring systems need to be accurate and reliable before incorporation in to closed-loop systems.

In conclusion, closed-loop systems are enabling more people with type 1 diabetes to reach recommended glucose targets, but further improvements in performance and safety are needed. Reflecting the success of closed-loop in type 1 diabetes, there are emerging indications where automated insulin delivery may also benefit people living with other types of diabetes.

Table 1 Features of commercially available hybrid closed-loop systems

	MiniMed 670G/770G/780G (Medtronic)	Control-IQ (Tandem)	DBLG1 (Diabeloop)	CamAPS FX (CamDiab)	Omnipod 5 (Insulet)	iLet bionic pancreas (BetaBionics)
Insulin pump	MiniMed 670G/770G/780G	t:slim X2	Kaleido pump	YpsoPump Dana pump	Omnipod patch pump	iLet pump
Glucose sensor	Guardian 3 (requires calibration) / Guardian 4	Dexcom G6/G7 Freestyle Libre 2 Plus	Dexcom G6	Dexcom G6 Freestyle Libre 3	Dexcom G6 FreeStyle Libre 2 Plus	Dexcom G6/G7
Algorithm	PID with insulin feedback. 780G also contains automated bolus insulin corrections	MPC algorithm uses pre-programmed basal rates and correction factors with automated bolus insulin corrections	MPC inspired, based on machine-learning within a physiological framework with an expert system and self-learning algorithms	MPC adaptive algorithm calculates and adjusts insulin sensitivity, carbohydrate bioavailability, and active insulin time	MPC algorithm calculates adaptive basal insulin rate based on average total daily insulin	Dosing decision software made up of 3 algorithms (basal insulin, bolus correction & meal aware algorithm).
Algorithm setup	TDD, weight, ICR, CF, basal rate	TDD, weight, ICR, CF, basal rate	TDD, weight, typical meal carbohydrate content, basal rate	TDD, weight	TDD, ICR, CF, basal rate	Weight
Adaptive learning	✓ overall	X	✓	✓ overall, diurnal, meals	✓ basal rate for each Pod	✓ overall, meal announcement algorithm
Bolusing from phone	X	X	X	✓	X	X

Personal glucose target	780G: 5.5, 6.1, 6.7 mmo/L	Sleep mode: 6.1 - 6.7 mmol/L	5.6 to 7.2 mmol/L	4.4 to 11.0 mmol/L	6.1 to 8.3 mmol/L	6.1, 6.7, 7.2 mmol/L
Activity / Ease-Off mode	✓	✓	✓	✓	✓	X
Boost mode	X	X	✓ (aggressiveness)	✓	X	X
Remote monitoring	780G: ✓ CareLink Connect app	✓ CGM only Dexcom Follow app	X	✓ CamAPS Companion app	✓ CGM only Dexcom Follow app Omnipod VIEW app	✓ CGM only Dexcom Follow app
Automated data upload	780G: ✓ CareLink	X	✓ YourLoops	✓ Glooko	✓ Glooko	✓ Beta Bionics Cloud
Insulin	Rapid	Rapid	Rapid	Rapid & ultra-rapid	Rapid	Rapid & Fiasp
Licence	T1D age 7+ (FDA and CE mark)	Diabetes requiring insulin age 6+ (FDA and CE mark)	T1D age 18+ (CE mark)	Diabetes requiring insulin age 1+ including pregnancy (CE mark)	T1D age 2+ (FDA and CE mark)	T1D age 6+ (FDA)

MPC, model predictive control; PID, proportional integral derivative; CGM, continuous glucose monitoring; T1D, type 1 diabetes; FDA, Food and Drug Administration; CE, Conformité Européenne.

Figure legends

Figure 1. The closed-loop ecosystem. Created with Biorender.





Figure 2. Variability of day-to-day insulin requirements as determined by closed-loop insulin delivery across different populations with diabetes (OP – outpatients, IP – inpatients).



Funding

Work in the authors group is supported by the National Institute for Health and Care Research, Cambridge Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care, or other funders.

Authors' relationships and activities

CKB has received consultancy fees from CamDiab, speaker honoraria from Ypsomed and is a member of the editorial board of Diabetologia. RH received speaker honoraria from Sandoz, Abbott Diabetes Care, and NovoNordisk, receiving consultancy fees from Abbott Diabetes Care, patents related to closed-loop, and is director at CamDiab.

For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) license to any Author Accepted Manuscript version arising from this submission.

Contribution Statement

All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.

References

1. Hermann JM, Miller KM, Hofer SE, et al. The Transatlantic HbA1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry. *Diabet Med.* 2020;37(5):848-55.
2. CDC. National Diabetes Statistics Report | Report 1: Care Processes and Treatment Targets, Detailed Analysis Report. CDC National Diabetes Audit 2021-22. 2022.
3. International Diabetes Federation. IDF Diabetes Atlas 2019.
4. Phillip M, Nimri R, Bergenstal RM, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. *Endocr Rev.* 2023.44(2):254-280.
5. Jiao X, Shen Y, Chen Y. Better TIR, HbA1c, and less hypoglycemia in closed-loop insulin system in patients with type 1 diabetes: a meta-analysis. *BMJ Open Diabetes Res Care.* 2022;10(2):e002633.
6. Karageorgiou V, Papaioannou TG, Bellos I, et al. Effectiveness of artificial pancreas in the non-adult population: A systematic review and network meta-analysis. *Metabolism.* 2019;90:20-30.
7. Bekiari E, Kitsios K, Thabit H, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. *BMJ.* 2018;361:k1310.
8. Ekhlaspour L, Town M, Raghinaru D, Lum JW, Brown SA, Buckingham BA. Glycemic outcomes in baseline hemoglobin a1c subgroups in the International Diabetes Closed-Loop trial. *Diabetes Technol Ther.* 2022;24(8):588-91.
9. Beck RW, Kanapka LG, Breton MD, et al. A meta-analysis of randomized trial outcomes for the t:slim X2 insulin pump with Control-IQ technology in youth and adults from age 2 to 72. *Diabetes Technol Ther.* 2023;25(5):329-42.
10. Bally L, Thabit H, Ruan Y, et al. Bolusing frequency and amount impacts glucose control during hybrid closed-loop. *Diabet Med.* 2018;35(3):347-51.

11. Castañeda J, Mathieu C, Aanstoot H-J, et al. Predictors of time in target glucose range in real-world users of the MiniMed 780G system. *Diabetes Obes Metab.* 2022;24(11):2212-21.
12. Daly AB, Boughton CK, Nwokolo M, et al. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. *Nat Med.* 2023;29(1):203-8.
13. Boughton CK, Tripyla A, Hartnell S, et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. *Nat Med.* 2021;27(8):1471-6.
14. Bally L, Thabit H, Hartnell S, et al. Closed-loop insulin delivery for glycemic control in noncritical care. *N Engl J Med.* 2018;379(6):547-56.
15. Boughton CK, Bally L, Martignoni F, et al. Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. *Lancet Diabetes Endocrinol.* 2019;7(5):368-77.
16. Levy CJ, Raghinaru D, Kudva YC, et al. Beneficial effects of Control-IQ automated insulin delivery in basal-bolus and basal-only insulin users with type 2 diabetes. *Clin Diabetes.* 2024;42(1):116-24.
17. Davis GM, Peters AL, Bode BW, et al. Safety and efficacy of the Omnipod 5 automated insulin delivery system in adults with type 2 diabetes: from injections to hybrid closed-loop therapy. *Diabetes Care.* 2023;46(4):742-50.
18. Sherwood JS, Castellanos LE, O'Connor MY, et al. Randomized trial of the insulin-only iLet Bionic Pancreas for the treatment of cystic fibrosis-related diabetes. *Diabetes Care.* 2024;47(1):101-8.
19. Godoi A, Reis Marques I, Padrão EMH, et al. Glucose control and psychosocial outcomes with use of automated insulin delivery for 12 to 96 weeks in type 1 diabetes: a meta-analysis of randomised controlled trials. *Diabetol Metab Syndr.* 2023;15(1):190.

20. Kimbell B, Rankin D, Hart RI, et al. Parents' experiences of using a hybrid closed-loop system (CamAPS FX) to care for a very young child with type 1 diabetes: Qualitative study. *Diabetes Res Clin Pract.* 2022;187:109877.
21. Rankin D, Kimbell B, Hovorka R, Lawton J. Adolescents' and their parents' experiences of using a closed-loop system to manage type 1 diabetes in everyday life: qualitative study. *Chronic Illn.* 2022;18(4):742-56.
22. Gianini A, Suklan J, Skela-Savič B, et al. Patient reported outcome measures in children and adolescents with type 1 diabetes using advanced hybrid closed loop insulin delivery. *Front Endocrinol.* 2022;13:967725.
23. Cobry EC, Bisio A, Wadwa RP, Breton MD. Improvements in parental sleep, fear of hypoglycemia, and diabetes distress with use of an advanced hybrid closed-loop system. *Diabetes Care.* 2022;45(5):1292-5.
24. Lawton J, Kimbell B, Closs M, et al. Listening to women: experiences of using closed-loop in type 1 diabetes pregnancy. *Diabetes Technol Ther.* 2023;25(12):845-55.
25. Akturk HK, Agarwal S, Hoffecker L, Shah VN. Inequity in racial-ethnic representation in randomized controlled trials of diabetes technologies in type 1 diabetes: critical need for new standards. *Diabetes Care.* 2021;44(6):e121-e123.
26. Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. *Lancet.* 2021;397(10270):208-19.
27. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. *N Engl J Med.* 2019;381(18):1707-17.
28. Benhamou PY, Franc S, Reznik Y, et al. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. *Lancet Digit Health.* 2019;1(1):e17-e25.
29. Russell SJ, Beck RW, Damiano ER, et al. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. *N Engl J Med.* 2022;387(13):1161-72.

30. Braune K, Lal RA, Petruželková L, et al. Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. *Lancet Diabetes Endocrinol.* 2022;10(1):58-74.
31. Considine EG, Sherr JL. Real-world evidence of automated insulin delivery system use. *Diabetes Technol Ther.* 2024;26(S3):32-7.
32. Choudhary P, Arrieta A, van den Heuvel T, Castaneda J, Smariotto V, Cohen O. Celebrating the data from 100,000 real-world users of the MiniMed™ 780G system in Europe, Middle East, and Africa collected over 3 years: from data to clinical evidence. *Diabetes Technol Ther.* 2024;26(S3):32-7.
33. Arrieta A, Battelino T, Scaramuzza AE, et al. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users. *Diabetes Obes Metab.* 2022;24(7):1370-9.
34. Messer LH, Breton MD. Therapy settings associated with optimal outcomes for t:slim x2 with Control-IQ technology in real-world clinical care. *Diabetes Technol Ther.* 2023;25(12):877-82.
35. Breton MD, Kovatchev BP. One year real-world use of the Control-IQ advanced hybrid closed-loop technology. *Diabetes Technol Ther.* 2021;23(9):601-8.
36. Benhamou PY, Adenis A, Lebbad H, et al. One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany. *Diabetes Obes Metab.* 2023;25(6):1607-13.
37. Alwan H, Wilinska ME, Ruan Y, Da Silva J, Hovorka R. Real-World Evidence Analysis of a Hybrid Closed-Loop System. *J Diabetes Sci Technol.* 2023:19322968231185348.
38. Forlenza GP, DeSalvo DJ, Aleppo G, et al. Real-world evidence of Omnipod(®) 5 automated insulin delivery system use in 69,902 people with type 1 diabetes. *Diabetes Technol Ther.* 2024. Online ahead of print.

39. Lum JW, Bailey RJ, Barnes-Lomen V, et al. A real-world prospective study of the safety and effectiveness of the Loop open source automated insulin delivery system. *Diabetes Technol Ther.* 2021;23(5):367-75.
40. Crabtree TSJ, Griffin TP, Yap YW, et al. Hybrid closed-loop therapy in adults with type 1 diabetes and above-target hba1c: a real-world observational study. *Diabetes Care.* 2023;46(10):1831-8.
41. Ng SM, Wright NP, Yardley D, et al. Real world use of hybrid-closed loop in children and young people with type 1 diabetes mellitus-a National Health Service pilot initiative in England. *Diabet Med.* 2023;40(2):e15015.
42. Lakshman R, Daly AB, Nwokolo M, et al. Variability of insulin requirements in adults with type 2 diabetes during fully closed-loop insulin delivery. *Diabetes Technol Ther.* 2023;25(6): 442-4.
43. Dovic K, Boughton C, Tauschmann M, et al. Young children have higher variability of insulin requirements: observations during hybrid closed-loop insulin delivery. *Diabetes Care.* 2019;42(7):1344-7.
44. Murphy HR, Howgate C, O'Keefe J, et al. Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study. *Lancet Diabetes Endocrinol.* 2021;9(3):153-64.
45. Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. *Lancet.* 2017 Nov 25;390(10110):2347-2359.
46. Lee TTM, Collett C, Bergford S, et al. Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. *N Engl J Med.* 2023;389(17):1566-78.
47. Renard E, Joubert M, Villard O, et al. Safety and Efficacy of sustained automated insulin delivery compared with sensor and pump therapy in adults with type 1 diabetes at high risk for hypoglycemia: a randomized controlled trial. *Diabetes Care.* 2023;46(12):2180-7.

48. Flatt AJ, Peleckis AJ, Dalton-Bakes C, et al. Automated insulin delivery for hypoglycemia avoidance and glucose counterregulation in long-standing type 1 diabetes with hypoglycemia unawareness. *Diabetes Technol Ther.* 2023;25(5):302-14.
49. National Institute for Health and Care Excellence. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. Technology appraisal guidance. TA943. Published December 2023.
50. Janez A, Battelino T, Klupa T, et al. Hybrid closed-loop systems for the treatment of type 1 diabetes: a collaborative, expert group position statement for clinical use in Central and Eastern Europe. *Diabetes Ther.* 2021;12(12):3107-35.
51. Lawton J, Kimbell B, Rankin D, et al. Health professionals' views about who would benefit from using a closed-loop system: a qualitative study. *Diabet Med.* 2020;37(6):1030-37.
52. Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM. One year clinical experience of the first commercial hybrid closed-loop system. *Diabetes Care.* 2019;42(12):2190-6.
53. Boughton CK, Hartnell S, Thabit H, et al. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study. *Diabetes Obes Metab.* 2021;23(6):1389-96.
54. Nwokolo M, Lakshman R, Hartnell S, et al. CamAPS FX Hybrid closed-loop with ultra-rapid lispro compared with standard lispro in adults with type 1 diabetes: a double-blind, randomized, crossover study. *Diabetes Technol Ther.* 2023;25(12):856-63.
55. Lee MH, Paldus B, Vogrin S, et al. Fast-acting insulin aspart versus insulin aspart using a second-generation hybrid closed-loop system in adults with type 1 diabetes: a randomized, open-label, crossover trial. *Diabetes Care.* 2021;44(10):2371-78.

56. Ozer K, Cooper AM, Ahn LP, Waggoner CR, Blevins TC. Fast acting insulin aspart compared with insulin aspart in the Medtronic 670G hybrid closed loop system in type 1 diabetes: an open label crossover study. *Diabetes Technol Ther.* 2021;23(4):286-92.
57. Boughton CK, Hartnell S, Lakshman R, et al. Fully closed-loop glucose control compared with insulin pump therapy with continuous glucose monitoring in adults with type 1 diabetes and suboptimal glycemic control: a single-center, randomized, crossover study. *Diabetes Care.* 2023;46(11):1916-22.
58. Tsoukas MA, Majdpour D, Yale JF, et al. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial. *Lancet Digit Health.* 2021;3(11):e723-e32.
59. Blauw H, Onvlee AJ, Klaassen M, van Bon AC, DeVries JH. Fully closed loop glucose control with a bihormonal artificial pancreas in adults with type 1 diabetes: an outpatient, randomized, crossover trial. *Diabetes Care.* 2021;44(3):836-8.
60. Haidar A, Yale JF, Lovblom LE, et al. Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial. *Diabetes Obes Metab.* 2021;23(6):1272-81.
61. Ilkowitz JT, Katikaneni R, Cantwell M, Ramchandani N, Heptulla RA. Adjuvant liraglutide and insulin versus insulin monotherapy in the closed-loop system in type 1 diabetes: a randomized open-labeled crossover design trial. *J Diabetes Sci Technol.* 2016;10(5):1108-14.
62. Corbett JP, Hsu L, Brown SA, et al. Smartwatch gesture-based meal reminders improve glycaemic control. *Diabetes Obes Metab.* 2022;24(8):1667-70.
63. Jacobs PG, Resalat N, Hilts W, et al. Integrating metabolic expenditure information from wearable fitness sensors into an AI-augmented automated insulin delivery system: a randomised clinical trial. *Lancet Digit Health.* 2023;5(9):e607-e17.